Download
slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
Sandro Mazzaferro Cattedra di Nefrologia I Facoltà Medicina e Chirurgia PowerPoint Presentation
Download Presentation
Sandro Mazzaferro Cattedra di Nefrologia I Facoltà Medicina e Chirurgia

Sandro Mazzaferro Cattedra di Nefrologia I Facoltà Medicina e Chirurgia

124 Views Download Presentation
Download Presentation

Sandro Mazzaferro Cattedra di Nefrologia I Facoltà Medicina e Chirurgia

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. XV Riunione del GdS DDialisi Peritoneale Bari, 19-20 Febbraio 2010 Question Time 2: In DP più vantaggi con la vitamina D o i VDRAs? Sandro Mazzaferro Cattedra di Nefrologia I Facoltà Medicina e Chirurgia “Sapienza” Università di Roma

  2. Why active Vitamin D therapy in PD • To suppress PTH: • But serum Ca Increases (also Ca balance) • But serum P Increases (also P balance) • To improve morbidity/mortality: • Linked to SH (bone disease/fractures and toxicity) • Linked to CV effects of CKD-MBD

  3. Bushinsky CJASN 2010

  4. Structures of Calcitriol and Paricalcitol CH3 H3C H3C CH3 CH3 OH OH CH3 CH3 Induzione VDR Intestino _ + CH2 Ca e P da Osso _ + HO HO OH OH 19-nor-1-a, 25-dihydroxyvitamin D2 1-a, 25-dihydroxyvitamin D3 Paricalcitol Calcitriol

  5. The Effects of 1,25-(OH)2D3 and 19-nor-1,25-(OH)2D2on Ionized Calcium in Uremic Rats 6.00 * = p<0.02 5.50 * 5.00 Ionized Calcium (mg/dL) 4.50 4.00 UREMIC N 0 2 4 8 8 25 75 ng 1.25-(OH)2D3 19-nor-1,25(OH)2D2 Slatopolsky AJKD 1995

  6. Effects of 1,25D-(OH)2D3 and 19-Nor-1,25-(OH)2D2 on Intestinal 1,25-(OH)2D3–VDR Binding in Uremic Rats *p<0.01 vs Uremic+1,25D-6ng (fmol/mg protein) 3H-1,25-(OH)2D3 Specific Binding * * * Uremic ng 0 2 6 25 100 Normal 1,25-(OH)2D3 19-nor-1,25-(OH)2D2 Slatopolsky AJKD 1995

  7. Dose-dependent Effects of 1,25D3 and 19-norD2 on Osteoclastic Resorption: Area Resorbed 120 1,25D3 100 19-norD2 80 Area Resorbed, % 108 1,25D3 60 40 20 0 10-11 10-10 10-9 10-8 10-7 10-6 Concentration, M Holliday S, JASN 11:1857, 2000

  8. Dose-dependent Effects of 1,25D3 and 19-norD2on Osteoclastic Resorption: Number of Pits 120 1,25D3 100 19-norD2 80 Number of Pits, % 10-8 1,25D3 60 40 20 0 1011 1010 109 108 107 106 Concentration, M Holliday S, JASN 11:1857, 2000

  9. Serum Calcium and Phosphorus in Placebo and Paricalcitol Treated Patients Placebo Paricalcitol 11 10 Calcium 9 8 7 6 Phosphorus Serum Calcium or Phosphorus mg/dl 5 4 3 2 1 0 1 2 3 4 5 6 7 8 9 10 11 12 Weeks Martin et al. JASN 9: 1427, 1998

  10. Lund et al Am J Neph, 2010Intestinal Ca Absorption in HD: comparison between Calcitriol and Paricalcitol 22 HD pts; PTH>200pg/ml Calcitriol i.v.; 2ug/HDx6 Paricalcitol i.v.; 6 ug/HDx6

  11. Potential advantages of Paricalcitol vs Calcitriol • PTH suppression with: • Lower calcemic effect; • Lower phosphate effect; • Better survival To date no RCT is available to clearly demonstrate the last statement.

  12. Sanchez NDT 2004 Low vs standard CaD in PD Not all ABD! CaD = 1,75 M CaD = 1,25 M 1 Year!

  13. PTH TCa OC No change!! Ca++ Mg P